ESR1 and breast cancer: It is known for being the precursor of compound H3B-6545, which was suggested for the potential treatment of endocrine therapy-resistant ERα+ BC harboring wild-type or mutant ESR1 (clinical trials: NCT03250676, NCT04568902, NCT04288089) [124].